Abstract: Exploring sensitive tumor markers for cervical carcinoma which can be used for correct treatment and prediction of prognosis. Methods A quantitative enzyme-linked immunosorbent assay (ELISA) was used to measure the concentrations of suPAR and SccAg from the sera of 57 patients with cervical carcinoma. The sera of 30 patients with leiomyoma were used as control. The t test, the analysis of variance and the multivariated analysis were used as statistical analysis. Results The mean level of suPAR in patients with cervical carcinoma was significantly higher than those with leiomyoma (P<0.01).The mean levels of suPAR and SccAg were significantly higher in patients with stage Ⅲ~Ⅳ than in patients with stageⅠ~Ⅱ (P<0.01). The mean levels of suPAR and SccAg in patients with non-residual tumor, in patients with negative pelvic lymph nodes and in patients whose tumor did not relapse with in six months after treatment were significantly lower than those in patients with residual tumor, positive pelvic lymph nodes and in patients whose tumor had relapsed, respectively (P<0.01). The mean SccAg level was not significantly influenced by post-treatment recurrence and residual tumor during operation (P>0.05). The positive rate of their expression in cervical carcinoma were 75.64% and 63.98%, respectively. Conclusion The high expression of suPAR and SccAg may indicate that they can be one of the characters for cervical carcinoma. SuPAR and SccAg can be used both as prognosis indicators and for post-operative radiotherapy in cervical carcinoma.